SARS-CoV-2 nucleocapsid protein dually regulates innate immune responses

This article has been Reviewed by the following groups

Read the full article See related articles

Abstract

The recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing global pandemic of COVID-19, may trigger immunosuppression in the early stage and a cytokine storm in the late stage of infection, however, the underlying mechanisms are not well understood. Here we demonstrated that the SARS-CoV-2 nucleocapsid (N) protein dually regulated innate immune responses, i.e., the low-dose N protein suppressed type I interferon (IFN-I) signaling and inflammatory cytokines, whereas high-dose N protein promoted IFN-I signaling and inflammatory cytokines. Mechanistically, the SARS-CoV-2 N protein interacted with the tripartite motif protein 25 (TRIM25), thereby dually regulating the phosphorylation and nuclear translocation of IRF3, STAT1 and STAT2. Additionally, low-dose N protein combined with TRIM25 could suppress retinoic acid-inducible gene I (RIG-I) ubiquitination and activation. Our findings revealed a regulatory mechanism of innate immune responses by the SARS-CoV-2 N protein, which would contribute to understanding the pathogenesis of SARS-CoV-2 and other SARS-like coronaviruses, and development of more effective strategies for controlling COVID-19.

Article activity feed

  1. SciScore for 10.1101/2021.02.17.431755: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Antibodies against STAT1, p-STAT1, and STAT2 were purchased from Abcam (Cambridge, MA, USA); anti-IRF3, anti-HA, anti-GST, anti-Flag, anti-GAPDH, CoraLite 594-conjugated IgG and CoraLite 488-conjugated IgG secondary antibodies were obtained from Proteintech (Rosemont, IL, USA); anti-TRIM25 and anti-pIRF3 antibodies were from Cell Signaling technology (Danvers, MA, USA); anti-pSTAT2 antibody was from Sigma-Aldrich (St. Louis, MO, USA).
    STAT1
    suggested: None
    p-STAT1
    suggested: None
    STAT2
    suggested: None
    anti-IRF3
    suggested: None
    anti-HA
    suggested: None
    anti-GST
    suggested: None
    anti-Flag
    suggested: None
    anti-GAPDH
    suggested: None
    USA)
    suggested: None
    anti-TRIM25
    suggested: None
    anti-pIRF3
    suggested: None
    anti-pSTAT2
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    Cells and antibodies: Human embryonic kidney cell HEK293T and hepatic carcinoma cell HepG2 were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (HyClone, Logan, UT) containing 10% inactivated fetal bovine serum (BBI, Shanghai, China), penicillin (100 IU/ml) and streptomycin (100 mg/ml) at 37 °C in a 5% CO2 atmosphere.
    HepG2
    suggested: None
    Briefly, HEK293T, HepG2 or sg25 cells were transfected with a control plasmid or protein expression plasmids together with the luciferase reporter plasmids using Viafect TM Transfection Reagent (Promega, Madison, WI, USA) or Lipofectamine TM 2000 (Invitrogen, San Diego, CA, USA).
    HEK293T
    suggested: None
    Software and Algorithms
    SentencesResources
    After cells were washed with PBST, they were blocked in 1% BSA and stained with primary antibodies, followed by staining with CoraLite 594- or CoraLite 488-conjugated IgG secondary antibodies (41).
    CoraLite
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


    Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 8 and 15. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.